Oxycodone controlled release - Purdue Pharma

Drug Profile

Oxycodone controlled release - Purdue Pharma

Alternative Names: OxiContin; Oxycodone controlled release - Purdue; Oxycodone extended release - Purdue; Oxycodone hydrochloride controlled-release; OxyContin; OxyContin Neo; OxyNeo

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Purdue Pharma
  • Developer Mundipharma International; Napp Pharmaceutical Group; Purdue Pharma; Shionogi
  • Class Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cancer pain; Pain; Postoperative pain

Most Recent Events

  • 08 Jul 2015 Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office confirms the patentability of all challenged claims in the inter partes review proceedings initiated by Purdue Pharma against two Depomed patents
  • 01 Jul 2014 Purdue completes a phase III trial in Pain (In adolescents, In children) in USA, Greece, Hungary, Israel, New Zealand, United Kingdom, Romania and Spain (NCT01192295)
  • 01 May 2014 Purdue Pharma completes a phase III extension trial for Pain in children and adolescents in USA and Israel (NCT01369615)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top